Upadacitinib Improves Ulcerative Colitis Outcomes at 12 Months
By Elana Gotkine HealthDay Reporter
MONDAY, Dec. 23, 2024 -- For patients with ulcerative colitis, upadacitinib is associated with improved disease-specific outcomes at 12 months compared with tofacitinib, according to a study published in the December issue of the American Journal of Gastroenterology.
Gursimran S. Kochhar, M.D., from the Allegheny Health Network in Pittsburgh, and colleagues conducted a retrospective cohort study to compare the effectiveness of upadacitinib and tofacitinib in patients with ulcerative colitis. Data were included for 526 patients in the upadacitinib cohort and 1,149 in the tofacitinib cohort.
The researchers observed no significant difference in the risk for the composite outcome of hospitalization requiring intravenous steroids and/or colectomy within six months in a propensity score-matched analysis. However, the risk for the composite outcome was significantly lower in the upadacitinib cohort versus the tofacitinib cohort within 12 months. The risk for intravenous steroid use did not differ significantly, but risk for colectomy was lower. In a sensitivity analysis, the risk for the composite outcome was significantly lower, including a lower risk for intravenous steroid use and colectomy, in the upadacitinib cohort versus tofacitinib cohort within 12 months.
"Our study utilizing real-world data showed that over a 12-month period following initiation of a Janus kinase inhibitor, upadacitinib use compared with tofacitinib is associated with improved disease-specific outcomes in patients with ulcerative colitis," the authors write.
Several authors disclosed ties to pharmaceutical companies, including AbbVie, which manufactures upadacitinib.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
Chronic Conditions and Their Age of Onset Predict Health Trajectory in IBD
MONDAY, March 24, 2025 -- Among people with inflammatory bowel disease (IBD), conditions developed at or before age 60 years and their age of onset are important for predicting...
IBD Activity May Increase Risk for Clostridioides Difficile Infection
WEDNESDAY, March 5, 2025 -- For patients with inflammatory bowel disease (IBD), risk factors associated with Clostridioides difficile infection (CDI) include recent diagnosis...
Inflammatory Bowel Disease Tied to Higher Risk for Heart Disease
WEDNESDAY, Feb 5, 2025 -- Male patients with inflammatory bowel disease (IBD) face a higher risk for ischemic heart diseases (IHDs), according to a study published in the March...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.